Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

Leukemia

Volumn 14, Issue 6, 2000, Pages 1136-1142

  Van Den Neste, E ^a   Louviaux, I ^b   Michaux, J L ^a   Delannoy, A ^a   Michaux, L ^a   Sonet, A ^b   Bosly, A ^b   Doyen, C ^b   Mineur, P ^c   Andre M ^c   Straetmans, N ^a   Coche, E ^a   Venet, C ^d   Duprez, T ^a   Ferrant, A ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c Department Hematology   (Belgium)

^d Service de Rheumatologie   (Belgium)

Author keywords

2 chloro 2' deoxyadenosine; Chronic lymphocytic leukemia; Cladribine; Cyclophosphamide; Non Hodgkin's lymphoma

Indexed keywords

CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MITOXANTRONE; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; INFECTION; MALE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0034129880     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401783     Document Type: Article

References (44)

1. Plunkett W, Gandhi V. Nucleoside analogs: cellular pharmacology, mechanisms of action, and strategies for combination therapy. In: Cheson BD, Keating MJ, Plunkett W (eds). Nucleoside Analogs in Cancer Therapy. Marcel Dekker: New York, 1997, pp 1-35.
2. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-1171.
3. Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996; 7: 373-379.
4. Foran JM, Rohatiner AZS, Coiffier B, Barbui T, lohnson SA, Hiddeman W, Radford JA, Norton AJ, Tollerfield SM, Wilson MP, Lister TA. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17: 546-553.
5. Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. Eur J Haematol 1999; 63: 35-41.
6. Morton J, Taylor K, Bunce I, Eliadis P, Rentoul A, Moore D, Kelly C, Wright S, Bashford J, Rodwell R, Rooney K, Mulligan S, Firkin F, Dodds A, Parkin J, Lowenthal R, Kimber R, Frost T, Grigg A, Goldstein D, Stone J, Lee N. High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Br J Haematol 1996; 95: 110-115.
7. Solal-Celigny P, Brice P, Brousse N, Caspard H, Bastion Y, Haioun C, Bosly A, Tilly H, Bordessoule D, Sebban C, Harousseau JL, Morel P, Dupas B, Plassart F, Vasile N, Fort N, Leporrier M. Phase II trial of fludarabine monophosphate as first-line teratment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514-519.
8. Liliemark J, Porwit A, Juliusson G. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1997; 25: 313-318.
9. French Cooperative Group on CLL. Multicentre prospective randomised trial of fludarabine vs cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432-1438.
10. Rai KR, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer CA. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG inter-group study. Blood 1996; 88: 141a.
11. Spriano M, Chiurazzi F, Cassibba V, Montillo M, Liso V, Mazza P, Molica S, Bruni R, Clavio M, Gobbi M, Santini G. Multicentre prospective randomised trial of fludarabine vs chlorambucil and prednisone in previously untreated patients with active B-chronic lymphocytic leukaemia (B-CLL): conclusive report. Haematologica 1999; 84: 1091.
12. Van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM, Gillis E, Leveugle P, Deneys V, Ferrant A, Van den Berghe G. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro2′-deoxyadenosine. Leukemia 1999; 13: 918-925.
13. Begleiter A, Wang H, Verburg L, Lee K, Israels LC, Mowat MRA, Johnston JB. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1996; 10: 1959-1965.
14. Gora-Tybor J, Robak T. The influence of 2-chlorodeoxyadenosine (2-CdA) alone and in combination with cyclophosphamide or methotrexate on normal and leukemic hematopoiesis. Adv Exp Med Biol 1994; 370: 129-130.
15. Hansson JA, Lewensohn R, Ringborg U, Nilson B. Formation and removal of crosslinks induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 1987; 47: 2631-2637.
16. 6-ethylguanine in DNA: relation to chemosensitivity in vitro and treatment outcome. Cancer Res 1994; 54: 4524-4531.
17. Geleziunas R, McQuillan A, Malapetsa A, Hutchinson M, Kopriva D, Wainberg MA, Hiscott J, Bramson J, Panasci L. Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 1991; 83: 557-564.
18. Koehl U, Ying Yang L, Li L, Nowak B, Ruiz van Haperen V, Keating M, Plunkett W. Effect of combined treatment with 4-hydroperoxycyclophosphamide and fludarabine on cytotoxicity and repair of damaged DNA. In: Hiddemann W et al (eds). Acute Leukemias VII. Experimental Approaches and Novel Therapies. Springer-Verlag: Berlin, 1998, pp 549-555.
19. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 1996; 2: 1731-1741.
20. Seto S, Carrera CJ, Wasson B, Carson DA. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J Immunol 1986; 8: 2839-2843.
21. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues - correlation with clinical course. Leukemia 1998; 12: 1230-1235.
22. Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 1999; 104: 612-613.
23. O'Brien S. Clinical challenges in chronic lymphocytic leukemia. Semin Hematol 1998; 35: 22-26.
24. Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M. Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. Eur J Haematol 1997; 59: 327-328.
25. Gillis S, Lossos I, Libster D, Paltiel O, Polliack A. Combination of fludarabine and cyclophosphamide as a salvage regimen for lymphoma - experience with 27 patients. Haematologica 1999; 84: 652.
26. Elias L, Stock-Novack D, Head DR, Grever MR, Weick JK, Chapman RA, Godwin JE, Metz EN, Appelbaum FR. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 1993; 7: 361-365.
27. Weiss M, Spiess T, Berman E, Kcmpin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994; 8: 1290-1293.
28. Tefferi A, Witzig TE, Reid JM, Li C-Y, Ames M. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol 1994; 12: 569-574.
29. Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999; 79: 1215-1219.
30. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for clinical protocols for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Am J Hematol 1996; 29: 152-163.
31. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddeman W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
32. Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. Leukemia 1996; 14: 2139-2144.
33. Delannoy A. 2-Chloro-2′-deoxyadenosine: clinical applications in hematology. Blood Rev 1996; 10: 148-166.
34. Juliusson G, Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. Leuk Lymphoma 1994; 13: 75-80.
35. luliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 1992; 327: 1056-1061.
36. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreef M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. New Engl J Med 1994; 330: 319-322.
37. Weber DM, Delasalle K, Gavino M, Wood A, Cabanillas F, Alexenian R. Primary treatment of Waldenstrom's macroglobulinemia with subcutaneous 2-chlorodeoxyadenosine and oral cyclophosphamide. Blood 1997; 90: 1592.
38. Lossos IS, Paltiel O, Polliack A. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 33: 155-160.
39. Lazzarino R, Orlandi E, Montillo M, Tedeschi A, Pagnucco C, Astori C, Corso A, Brusamolino E, Simoncini L, Morra E, Bernasconi C. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 59-64.
40. Hochster H, Oken M, Winter J, Gordon L, Raphael B, Bennett J, Horning S, Cassileth P. Prolonged time to progression (TTP) in patients with low grade lymphoma (LGL) treated with cyclophosphamide (C) and fludarabine (F). Proc Am Soc Clin Oncol 1998; 17: 66.
41. Hoffman M, Tallman MS, Hakimian D, Janson D, Hogan D, Variakogis D, Kuzel T, Gordon LI, Rai K. 2-chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 788-792.
42. Robak T, Blonski JZ, Urbanska-Rys H, Blasinska-Morawiec M, Skotnicki AB. 2-chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old or younger. Leukemia 1999; 13: 518-523.
43. Van Den Neste E, Delannoy A, Vandercam B, Bosly A, Ferrant A, Mineur P, Montfort L, Martiat P, Straetmans N, Filleul B, Michaux JL. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56: 235-240.
44. Cheson BD, Vena DA, Barett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Onco/ 1999; 17: 2454-2460.